97 related articles for article (PubMed ID: 24065837)
1. Complexities of HCV management in the new era of direct-acting antiviral agents.
Rosenberg WM; Tanwar S; Trembling P
QJM; 2014 Jan; 107(1):17-9. PubMed ID: 24065837
[TBL] [Abstract][Full Text] [Related]
2. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
3. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
[TBL] [Abstract][Full Text] [Related]
4. Virological tools to diagnose and monitor hepatitis C virus infection.
Chevaliez S
Clin Microbiol Infect; 2011 Feb; 17(2):116-21. PubMed ID: 21054664
[TBL] [Abstract][Full Text] [Related]
5. Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients.
Donato MF; Bastiampillai AJ; Manini M; Monico S
J Antimicrob Chemother; 2013 Apr; 68(4):974-5. PubMed ID: 23221629
[No Abstract] [Full Text] [Related]
6. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
7. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.
Soriano V; Labarga P; Vispo E; Fernández-Montero JV; Barreiro P
Infect Dis Clin North Am; 2012 Dec; 26(4):931-48. PubMed ID: 23083825
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus infection management in 2012.
Van Gulick JJ; Lamers MH; Drenth JP
Panminerva Med; 2012 Mar; 54(1):1-9. PubMed ID: 22278112
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus viral assays in the direct-acting antiviral era.
Vierling JM
Clin Liver Dis; 2013 Feb; 17(1):27-45. PubMed ID: 23177281
[TBL] [Abstract][Full Text] [Related]
12. [Chronic hepatitis C].
Grammatikos G; Sarrazin C
Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
[TBL] [Abstract][Full Text] [Related]
13. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
[TBL] [Abstract][Full Text] [Related]
14. Drugs in development for chronic hepatitis C: a promising future.
Pockros PJ
Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
16. How to use virological tools for the optimal management of chronic hepatitis C.
de Leuw P; Sarrazin C; Zeuzem S
Liver Int; 2011 Jan; 31 Suppl 1():3-12. PubMed ID: 21205131
[TBL] [Abstract][Full Text] [Related]
17. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
18. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of hepatitis C: current status and perspectives].
Pol S; Corouge M
Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
